NEUROLITE Drug Patent Profile

Which patents cover Neurolite, and when can generic versions of Neurolite launch?

Neurolite is a drug marketed by Lantheus Medcl and is included in one NDA.

The generic ingredient in NEUROLITE is technetium tc-99m bicisate kit. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m bicisate kit profile page.

Summary for NEUROLITE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	20
Drug Prices:	Drug price information for NEUROLITE
What excipients (inactive ingredients) are in NEUROLITE?	NEUROLITE excipients list
DailyMed Link:	NEUROLITE at DailyMed

See drug prices for NEUROLITE

US Patents and Regulatory Information for NEUROLITE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lantheus Medcl	NEUROLITE	technetium tc-99m bicisate kit	INJECTABLE;INJECTION	020256-001	Nov 23, 1994		RX	Yes	Yes

Expired US Patents for NEUROLITE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lantheus Medcl	NEUROLITE	technetium tc-99m bicisate kit	INJECTABLE;INJECTION	020256-001	Nov 23, 1994	5,279,811
Lantheus Medcl	NEUROLITE	technetium tc-99m bicisate kit	INJECTABLE;INJECTION	020256-001	Nov 23, 1994	5,431,900

International Patents for NEUROLITE

See the table below for patents covering NEUROLITE around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	3871173
Spain	2042609
Greece	3004986
South Africa	8801136

Supplementary Protection Certificates for NEUROLITE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
0279417	95C0005	Belgium		PRODUCT NAME: DICHLORHYDRATE DE BICISATE; NATIONAL REGISTRATION NO/DATE: 923 IS 16 F 12 19950316; FIRST REGISTRATION: DK DK.R.11. 931008 19931008

NEUROLITE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Neurological Disorder Drugs: A Comprehensive Overview

Introduction

The market for neurological disorder drugs is experiencing significant growth, driven by various factors including an increasing prevalence of neurological diseases, advancements in therapeutic options, and government initiatives. Here, we will delve into the market dynamics and financial trajectory of this sector, highlighting key trends, drivers, and challenges.

Market Size and Growth

The neurological disorder drugs market has shown robust growth in recent years. In 2023, the market size was valued at $79.67 billion and is projected to reach $84.60 billion in 2024, with a compound annual growth rate (CAGR) of 6.2%. By 2028, the market is expected to grow to $108.05 billion at a CAGR of 6.3%[1].

Drivers of the Market

Several factors are driving the growth of the neurological disorder drugs market:

Increasing Prevalence of Neurological Diseases

The aging global population and increased exposure to environmental, metabolic, and lifestyle risk factors have led to a rise in neurological diseases. This increase is propelling the demand for effective treatments[1].

Expanding Therapeutic Options

The market is witnessing a surge in personalized therapies and disease-modifying treatments. Advancements in drug design, neuroimaging, and genetic research are also contributing to the growth[1].

Government Initiatives and Healthcare Expenditure

Government initiatives and an increase in healthcare expenditure are supporting the development and accessibility of neurological disorder drugs[1].

Market Segmentation

The neurological disorder drugs market is segmented in several ways:

By Drug Class

• Cholinesterase Inhibitors
• N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
• Antiepileptic, Antipsychotic, and Antidepressant Drugs
• Other Drug Classes[1].

By Indication

• Epilepsy
• Alzheimer’s Disease
• Parkinson’s Disease
• Multiple Sclerosis
• Cerebrovascular Disease
• Other Indications[1].

By Route of Administration

• Oral
• Parenteral
• Other Routes of Administration[1].

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels[1].

By End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Other End Users[1].

Regional Analysis

North America was the largest region in the neurological disorder drugs market in 2023, while the Asia-Pacific region is expected to be the fastest-growing in the forecast period. The market report covers countries such as the USA, UK, Canada, and several others across different regions[1].

Key Trends and Strategies

Advancements in Drug Design

Advances in drug design are leading to more effective and targeted therapies. For instance, the use of nanotechnology in drug delivery has improved drug stability and ensured sustained release, particularly in neurology[3].

Neuroimaging and Genetic Research

Advancements in neuroimaging and genetic research are enhancing the understanding and treatment of neurological disorders. These technologies help in early diagnosis and personalized treatment plans[1].

Collaborations and Licensing Agreements

Companies are engaging in collaborations and licensing agreements to accelerate the development and commercialization of new drugs. For example, Eli Lilly's decision to split its division for neurology and inflammatory diseases aims to shorten the path to market for its experimental Alzheimer’s treatment[4].

Emergence of Regenerative Medicine

Regenerative medicine is emerging as a promising area in the treatment of neurological disorders. This approach focuses on repairing or replacing damaged tissues and cells, offering new hope for patients with chronic conditions[1].

Financial Performance of Key Players

Neuronetics Inc.

Neuronetics Inc., a company specializing in neurological treatments, reported a revenue of $16.5 million in the second quarter of 2024, with a 7% decrease compared to the same period in 2023. However, the company saw an increase in U.S. treatment session revenue and NeuroStar Advanced Therapy System sales in the third quarter of 2024, indicating positive momentum in their strategic initiatives[2][5].

Challenges in the Market

High Development Costs

The development of neurological disorder drugs is highly costly and time-consuming. The failure rate of drugs in clinical trials is high, which can be a significant deterrent for investment[4].

Regulatory Hurdles

Regulatory challenges and stringent approval processes can delay the market entry of new drugs. For instance, the problematic insurance coverage for drugs like Aduhelm has posed challenges for companies[4].

Market Competition

The market is highly competitive, with several major pharmaceutical companies vying for market share. New entrants, such as gantenerumab by Roche, are expected to further intensify the competition[4].

Impact of Macro Economic Scenario

High Inflation

High inflation can impact the market by increasing the cost of raw materials and manufacturing, potentially affecting the pricing and profitability of neurological disorder drugs[1].

Ukraine-Russia War

The Ukraine-Russia war has disrupted global supply chains and can affect the availability and cost of raw materials, impacting the production and distribution of these drugs[1].

COVID-19 Impact

The COVID-19 pandemic has accelerated the adoption of digital technologies in healthcare, including telemedicine and remote monitoring, which can influence the delivery and accessibility of neurological treatments[1].

Future Outlook

The future of the neurological disorder drugs market looks promising with several advancements on the horizon:

Nanotechnology in Neurology

Nanotechnology is expected to play a significant role in improving drug delivery systems, ensuring sustained release and better efficacy. The global nanotechnology drug delivery market is projected to reach $153 billion by 2030, with notable advances in neurology[3].

Personalized Therapies

Personalized therapies tailored to individual patient needs are becoming more prevalent. This approach is expected to improve treatment outcomes and patient satisfaction[1].

Regenerative Medicine

Regenerative medicine is poised to revolutionize the treatment of neurological disorders by focusing on repairing or replacing damaged tissues and cells[1].

Key Takeaways

• The neurological disorder drugs market is growing strongly, driven by increasing prevalence of diseases and advancements in therapeutic options.
• The market is segmented by drug class, indication, route of administration, distribution channel, and end-users.
• Key trends include advancements in drug design, neuroimaging, genetic research, collaborations, and the emergence of regenerative medicine.
• Companies like Neuronetics Inc. are showing positive financial performance despite some challenges.
• The future outlook is promising with significant contributions from nanotechnology and personalized therapies.

FAQs

What is the current market size of the neurological disorder drugs market?

The neurological disorder drugs market size was valued at $79.67 billion in 2023 and is expected to reach $84.60 billion in 2024[1].

What are the main drivers of the neurological disorder drugs market?

The main drivers include the increasing prevalence of neurological diseases, expanding therapeutic options, government initiatives, and growth in healthcare expenditure[1].

Which region is expected to be the fastest-growing in the neurological disorder drugs market?

The Asia-Pacific region is expected to be the fastest-growing in the forecast period[1].

How is nanotechnology impacting the neurological disorder drugs market?

Nanotechnology is improving drug stability, ensuring sustained release, and enhancing the efficacy of treatments, particularly in neurology[3].

What are some of the challenges faced by the neurological disorder drugs market?

Challenges include high development costs, regulatory hurdles, market competition, and the impact of macroeconomic scenarios such as high inflation and global conflicts[1][4].

Sources

1. The Business Research Company: Neurological Disorder Drugs Global Market Report 2024.
2. Neuronetics: Neuronetics Reports Record Second Quarter 2024 Financial and Operating Results.
3. GlobeNewswire: Global Nanotechnology Drug Delivery Market Projected to Reach $153 Billion by 2030.
4. PharmTech: What is Wrong with the Neuroscience Drug Market?
5. BioSpace: Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results.